All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Philadelphia-positive (Ph+) ALL?
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?
Short presents promising safety and efficacy data from a single-arm phase II study investigating a combination of ponatinib + blinatumomab, in adult patients with newly diagnosed or relapsed/refractory Ph+ ALL.
Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with R/R Ph+ ALL?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Nicholas J. Short, MD Anderson Cancer Center,...
What are the main advances in patient care that we are seeing with novel agents for leukemia?
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, What are...
Subscribe to get the best content related to ALL delivered to your inbox